SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Earth Science Tech, Inc. (OTC: ETST) has been hard at work on a number of developments as of late. They recently bolstered their Scientific Advisory Board with a team of accomplished medical doctors, and have begun developing high industrial hemp CBD oil products in three consistencies and a variety of different flavors based on their two U.S. Provisional Patent Applications, N. 62/061,577 and 62/102,538.

These products will be packaged and sold as nutraceuticals, and the company recently announced they are nearly ready to apply for a natural product number so they can seek FDA approval prior to putting the products up for sale in the U.S. and Canada.

Additionally, the company’s Chief Operating Officer and President, Nickolas S. Tabraue, has been working diligently on candy-like High-Grade Hemp CBD Strawberry Orange Blossom supplements and a unique CBD line for pets. The company is planning to launch these, along with a new line of edibles by mid-May.

The company also teased in their most recent press release that a “few major breakthroughs” will be shared with shareholders pending finalization and more concrete developments. With the company looking strong on all fronts with their drug development regimen, this company could quickly become one of the more prominent cannabis stocks on the OTC markets.